ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer
Göster/ Aç
Tarih
2022Yazar
Colombo, N.
Coleman, R. L.
Wu, X.
Kose, F.
Wenham, R.
Sebastianelli, A.
Hasegawa, K.
Zsiros, E.
Rouge, T. De La Motte
Bidzinski, M.
McNeish, I.
Sehouli, J.
Korach, J.
Debruyne, P. R.
Kim, J-W.
De Melo, A. C.
Peng, X.
Bogusz, A. M.
Yamada, K.
Monk, B. J.